Premium
Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis
Author(s) -
Pelz Joerg O.W.,
Stojadinovic Alexander,
Nissan Aviram,
Hohenberger Werner,
Esquivel Jesus
Publication year - 2008
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21169
Subject(s) - medicine , gastroenterology , disease , cancer , peritoneal carcinomatosis , chemotherapy , surgery , colorectal cancer
Systemic therapy and cytoreduction (CRS) with hyperthermic intra‐peritoneal chemotherapy (HIPEC) may benefit selected patients with carcinomatosis from colon cancer (PC). This study presents the results of a consecutive series of patients evaluated under a single strategy. Patients and Methods Forty patients with PC referred for CRS were evaluated. Evaluation of their treatment was determined according to disease severity scored on a 3‐point scale including: (1) symptoms, (2) extent of peritoneal dissemination (PCI), and (3) primary tumor histology. Overall survival (OS) was analyzed using Kaplan–Meier product‐limit method and log rank testing according to four tiers of estimated disease severity based on the above parameters. Results For patients with disease severity score I, II, III, and IV, 2‐year OS following treatment was 100%, 80%, 80%, and 0%, respectively. Median OS with most advanced disease (IV: n = 20) was 5 months versus 36 months for disease of lesser severity (I–III: n = 20; P < 0.001; RR = 0.2; 95%CI 0.1–0.5). Advanced disease (IV) was an independent predictor of adverse outcome on multivariate analysis with 2.6‐fold increased likelihood of mortality. Conclusion A treatment strategy based on disease severity determined at time of diagnosis, stratifies patients into prognostic groups and may improve selection of patients for appropriate therapy. J. Surg. Oncol. 2009;99:9–15. Published 2008 Wiley‐Liss, Inc.